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An increasing rate of antidepressant trials fail due to large placebo responses. This analysis aimed to
identify variables inﬂuencing signal detection in clinical trials of major depressive disorder. Patient-level
data of randomized patients with a duloxetine dose 60 mg/day were obtained from Lilly. Total scores of
the Hamilton Depression Rating scale (HAM-D) were used as efﬁcacy endpoints. In total, 4661 patients
from 14 studies were included in the analysis. The overall effect size (ES), based on the HAM-D total score
at endpoint, between duloxetine and placebo was 0.272. Although no statistically signiﬁcant in-
teractions were found, the following results for factors inﬂuencing ES were seen: a very low ES (0.157)
in patients in the lowest baseline HAM-D category and in patients recruited in the last category of the
recruitment period (0.122). A higher ES in patients recruited in centers with a site-size at but not more
than 2.5 times the average site-size for the study (0.345). Study characteristics that resulted in low
signal detection in our database were: <80% study completers, a HAM-D placebo response >5 points, a
high variability of placebo response (SD > 7 points HAM-D), >6 post baseline visits per study, and use of
an active control drug. Simpler trial designs, more homogeneous and mid-sized study sites, a primary
analysis based on a higher cutoff blinded to investigators to avoid the inﬂuence of score inﬂation in mild
patients and, if possible, studies without an active control group could lead to a better signal detection of
antidepressive efﬁcacy.
 2014 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.1. Objectives of the study and background
Placebo-controlled studies of antidepressants oftendemonstrate
a large placebo response resulting in relatively small effect size (ES)
between placebo and active drug in patients suffering from major
depressive disorder (MDD). This results in reduced signal detection,
i.e. the failure to conﬁrm a treatment effect. It has been shown that
this effect has been increasing over time (Khin et al., 2011;þ39 3454330339 (mobile);
ancini).
er Ltd. Open access under CC BY-NC-NRutherford and Roose, 2013), and around 50% of the clinical trials
with active antidepressants fail to show any signiﬁcant difference
from placebo (Khan et al., 2003a, 2003b; Gelenberg et al., 2008;
Turner et al., 2008; Khin et al., 2011). The inevitable outcome is
delay and increasing inefﬁciency in the development of new anti-
depressants. Several authors have tried to identify factors and pa-
tient characteristics as predictors for increasing signal detection in
clinical trials with antidepressants. Khan et al. (2004) noted that the
severity of depressive symptoms at baseline, ﬂexible dosing, fewer
treatment arms, and a lower percentage of female patients were
signiﬁcantly associated with successful trials. Khin et al. (2011)
conﬁrmed the decline of treatment effects in MDD studies over a
25 years period, suggesting that the baseline disease severity of
patients included in clinical trials seems to be a more important
factor in study outcome than other factors. Kirsch et al. (2008) and
Fournier et al. (2010) found that the magnitude of beneﬁt of anti-
depressant medication compared with placebo increases with theD license.
Table 1
Design characteristics of the 14 studies from the duloxetine integrated database included in the Effect Size analysis.
Study
ID
Protocol title Study
phase
Year of
protocol
Publications Length of acute
phase (weeks)a
Number of
post-baseline
visits
Placebo
controlled
Active
controlled
Number of
treatment arms
Patients
assigned to
placebo (%)
Ratio of
completers
Ratio of
placebo
respondersb
Number of
countries
in study
HMAQA Duloxetine Versus Placebo in the
Treatment of Major Depression
II 1998 Goldstein et al., 2002 8 8 yes yes 3 40.46 65.32 48.57 1
HMAQB Duloxetine Versus Placebo in the
Treatment of Major Depression
II 1998 Nemeroff et al., 2002,
Mallinckrodt et al., 2003
8 8 yes yes 3 38.66 63.92 44 1
HMATA Duloxetine Versus Placebo and Paroxetine
in the Acute Treatment of Major
Depression
III 2000 Nemeroff et al., 2002
Mallinckrodt et al., 2003
8 5 yes yes 4 25.42 68.64 43.33 1
HMATB Duloxetine Versus Placebo and Paroxetine
in the Acute Treatment of Major
Depression
III 2000 Goldstein et al., 2004 8 5 yes yes 4 25.21 59.21 42.7 1
HMAYA Duloxetine Versus Placebo and Paroxetine
in the Treatment of Major Depression
III 2000 Detke et al., 2004 8 5 yes yes 4 25.34 86.65 69.89 6
HMAYB Duloxetine Versus Placebo and Paroxetine
in the Treatment of Major Depression
III 2000 Perahia et al., 2006 8 5 yes yes 4 25.26 91.07 78.79 7
HMBHA Duloxetine Once-Daily Dosing Versus
Placebo in the Acute Treatment of Major
Depression
III 2000 Detke et al., 2002a 9 6 yes no 2 49.8 67.76 36.07 1
HMBHB Duloxetine Once-Daily Dosing Versus
Placebo in the Acute Treatment of Major
Depression
III 2000 Detke et al., 2002b 9 6 yes no 2 52.06 62.92 48.2 1
HMBV Duloxetine Versus Placebo in the
Treatment of Elderly Patients With Major
Depressive Disorder
IV 2002 Raskin et al., 2008a,
Wise et al., 2007,
Raskin et al., 2008b,
Raskin et al. 2007 c
8 4 yes no 2 33.44 77.81 35.58 2
HMCB Duloxetine Once-Daily Dosing Versus
Placebo in Patients with Major Depression
and Pain
IIIb 2001 Brannan et al., 2005 7 5 yes no 2 50 65.6 51.77 1
HMCR Duloxetine Versus Escitalopram and
Placebo in the Treatment of Patients With
Major Depression
IIIb 2003 Nierenberg et al., 2007 8 6 yes yes 3 20.03 71.93 46.72 1
HMFA Cymbalta Vs Placebo in Long-Term
Treatment Late-Life MDD
IV 2006 Robinson et al., 2014 12 5 yes no 2 32.7 69.46 55.37 4
HMFS MDD efﬁcacy in depressive sympt
improvements and usual fx
IV 2007 Oakes et al., 2012 36 11 yes no 2 33.03 71.89 63.07 2
HQAC Validation of Daily Telephone Self-
Assessment in the Study of Antidepressant
Treatment Outcome
II 2002 Mundt et al., 2007b 4 4 yes no 3 50 94.29 42.86 1
a Without placebo lead-in phase.
b Response was deﬁned as 30% reduction from baseline (LOCF) on the HAM-D 17 total score at endpoint.
c HMBV primary manuscript.
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increasingdifferencebetween theeffectof antidepressant drugs and
placebo inmore severe patients is due toan increasingefﬁcacyof the
medication or to a declining placebo effect (Fournier et al., 2010), or
to a methodological bias underlying such ﬁndings (Höschl, 2008;
Turner and Rosenthal, 2008; Fountoulakis and Möeller, 2011;
Schacht et al., 2013). Furthermore, various approaches have been
used to try to identify the reasons for these unduly large placebo
responses,whichhave increased further inmore recent studieswith
several antidepressants (Khan et al., 2010).
Apart from the fact that patients selected for clinical trials
suffering from psychiatric disorders, such as MDD, are generally
prone to large placebo effects, many aspects of the design of anti-
depressant trials may have a signiﬁcant impact on treatment out-
comes; thus in recent years, discussion has focused on the design
features of current MDD studies that might artiﬁcially inﬂate pla-
cebo responses. For example, Mundt et al. (2007a) pointed out that,
further to the strong placebo response, methodological factors such
as patient selection and competitive enrollment targets, as well as a
tendency to inﬂate baseline scores to enroll patients, contribute to
increasing rates of failed antidepressant trials. Therefore, other
authors have tried to identify methods to improve signal detection
(Gelenberg et al., 2008). For example, Mallinckrodt et al. (2007)
suggested that the use of mixed model repeated measure
(MMRM) analysis and some Hamilton Depression Rating scale
(HAM-D) subscales among other factors could minimize the high
rate of false positive and false negative ﬁndings in trials with an-
tidepressants. Very recently, Gueorguieva et al. (2011) have pro-
vided inspiring and convincing proof that some patients receiving
medication during an antidepressant clinical trial do even worse
than patients receiving placebo. The hidden bipolarity of some
patients included in MDD clinical trials, or early discontinuation
from the drug in some enrolled patients, could partially explain
such ﬁndings. Furthermore, these authors challenged the belief
that placebo response is associated predominantly with rapid and
transient clinical improvement, proving instead that placebo
response differences are a dimensional rather than a categorical
characteristic. Based on these unresolved questions and on the
extensive debate present in the literature and among clinicians, the
aim of the presented analysis was to comprehensively evaluate
design aspects of all acute placebo-controlled studies in the
duloxetine integrated database and their inﬂuence on ES compared
to placebo. Study design features, including the region where the
study was performed, patient characteristics, and technical aspects
of study management, such as the time-point of recruitment rela-
tive to the study progress (i.e. early or late during the study), size of
the study site (i.e. the number of patients recruited), and the vari-
ability of patient parameters at baseline were evaluated.
This analysis should enable us to identify speciﬁc parameters
that could lead to a smaller placebo response, a larger ES, better
signal detection, and consequently to a higher success rate for
placebo-controlled clinical trials with antidepressants.2. Materials and methods
This analysis was based on individual patient data from a
database including all patients participating in clinical trials with
duloxetine used as an antidepressant performed by Eli Lilly & Co. All
studies were performed according to the appropriate version of the
Declaration of Helsinki and the study designs were approved by the
appropriate ethics committees. All participants provided informed
consent after being informed about the nature of the procedures of
the respective study. Results of the individual studies were previ-
ously reported as detailed in Table 1. From this overall database,studies were included in the present meta-analysis if they met the
following criteria:
 Studies investigating efﬁcacy and safety of duloxetine in MDD
 Randomized controlled studies (placebo with or without active
comparator control)
 Studies conducted in patients with acute depressive symptoms
(i.e. data from patients in relapse prevention studies were
excluded)
 At least 1 duloxetine arm with a dose 60 mg/day
 Studies with symptoms measured using HAM-D as endpoint.
Table 1 presents the list of studies included in the analysis with
their key study design features and literature references.
2.1. Statistical analyses
The analysis population used for the statistical analyses
comprised all randomized patients excluding patients in duloxetine
treatment arms that received a dose <60 mg/day. This population
will be referred to as all randomized patients.
Study overview and study design parameters were summarized
by study. Size of sites (i.e. the number of patients) was analyzed as
absolute size and relative size (compared to the median site size of
all sites within the study) by region, by study, and by country. In
addition, patient demographic, disease, pre-treatment, and base-
line characteristics were analyzed. All analyses for study and pa-
tient characteristics were done using descriptive statistics andwere
based on all randomized patients.
Efﬁcacy endpoints were analyzed using an Analysis of Covari-
ance (ANCOVA; last observation carried forward [LOCF]) based
meta-analysis or with meta-regression methodology using infor-
mation on a study-level and on site-level. The population used was
all randomized patients without missing data. All p-values and
conﬁdence intervals are unadjusted for multiplicity and cannot be
considered conﬁrmatory.
The ANCOVA model was calculated for each group, including
treatment, patient characteristics, and their interaction as ﬁxed
effects, and the baseline value of the efﬁcacy endpoint as covariate.
ES in each model was calculated for least square mean (LSMEAN)
differences, divided by the standard deviation (SD) of the residuals
provided by themodel of this group. Overall LSMEAN estimates and
ES were calculated as a weighted mean of the corresponding esti-
mates within study, with weights based on study variance,
assuming a ﬁxed study effect.
The following patient level parameters were included in the
ANCOVA meta-analysis models: HAM-D total score as efﬁcacy
endpoint and the following study and study site characteristics:
 Absolute size of site (number of patients per site)
 Relative size of site (number of patients per site divided by
average number of patients per site in the respective study)
 Time since recruitment started (<50 days, 50e100 days, 100e
150 days, >150 days)
 Psychiatrist/psychologist (yes/no, missing ¼ no)
 Number of studies per site (1/>1)
 Academic site (yes/no)
 Cluster score measuring investigator enrollment history in
previous trials taken from a clinical operations database.
Two additional ANCOVAswere calculated,with treatment and the
baseline value of the efﬁcacy endpoint as covariates, whereby one
model was used per study (model 1) or per site (model 2). The
resulting LSMEAN difference estimates were used as a basis for the
meta-regressionmodels. For each study/site characteristic of interest
M. Mancini et al. / Journal of Psychiatric Research 51 (2014) 21e2924and group comparison, a meta-regressionmodel was used. For these
analyses, the standard errorsof LSMEANestimates, asprovidedby the
basisANCOVAmodel,wereused asweights. Theonlyexceptions from
this are the analyses of size of sites, where the standard error corre-
lates with the variable of interest and therefore equal weights were
applied.
A simple meta-regression was used for all categorical variables.
For all continuous variables, a meta-regression model with poly-
nomials of the covariate of interested was performed, as well as a
meta-regression for categorization of the covariate of interested.
The results from the meta-regression on the continuous variable
were further presented graphically, once for all group comparisons
(not shown), and once, inmore detail, for the placebo vs. duloxetine
comparison.
The following study or study site parameters were included in
the ANCOVA meta-regression analysis models (i.e. based on study
or site level) on the HAM-D total score:
 Size of site
 Relative size of site
 Time to the start of recruitment
 Time to recruitment (within site)
 Number of studies per site (1/>1)
 Academic site (yes/no)
 Cluster score
 Proportion of placebo patientsTable 2
Patient demographics, disease characteristics, and site size of the patients from the dulo
Parameter Duloxetine (N ¼ 2385)
Patient demographics
Age [years] mean (SD) 48.3 (16.39)
Sex [female] n (%) 1549 (64.9)
Ethnicity n (%)
White 1904 (79.8)
Black 206 (8.6)
Other 275 (11.5)
Geographical region n (%)
US 1887 (79.1)
Europe 350 (14.7)
Other 148 (6.2)
Disease characteristicsa
Patients with 1 pre-existing condition 1746 (73.2)
Number of previous episodes, median (IQR) 2 (1; 4)
Duration of current episode, [months] median (IQR) 4.6 (1.8; 12.0)
Patients with 1 previous medication for MDD, n (%) 1316 (55.2)
CGI-S at baseline, mean (SD) 4.29 (0.68)
HAM-D 17 total score at baseline, mean (SD) 20.2 (4.99)
Median (IQR) 220 (17.0; 3.0)
US (N ¼ 3730) Europe
Size of site (patients/site) Patients, n (%)
<10 565 (15.1) 30 (4
10e14 667 (17.9) 119 (1
15e19 607 (16.3) 146 (2
20e24 598 (16.0) 150 (2
25e29 564 (15.1) 25 (3
30 729 (19.5) 214 (3
Mean (SD) 22.3 (14.59) 25.5 (1
Relative size of site Patients, n (%)
<0.5 246 (6.6) 23 (3
0.5e<1 903 (24.2) 243 (3
1e<1.5 1041 (27.9) 204 (2
1.5e<2 840 (22.5) 63 (9
2e<2.5 312 (8.4) 0 (0
2.5e<3 112 (3.0) 151 (2
3 276 (7.4) 0 (0
Mean (SD) 1.481 (0.90) 1.385 (0
a Some variables were not collected in all studies; CGI-S: clinical global impression e s
MDD: major depressive disorder; N: number of patients; n: number of patients with res Proportion of completers
 Proportion of 30% HAM-D placebo responders
 Change in HAM-D total score in placebo group
 SD of change in HAM-D total score in placebo group
 Proportion of treatment-emergent adverse events in placebo
group
 Number of post-baseline visits
 Active controlled study (yes/no)
 Year of protocol
 Number of post-baseline visits per week
 Titration of duloxetine at study start (yes/no)
 Placebo lead-in phase (yes/no)
 Number of countries in study
 Fixed vs. ﬂexible duloxetine dose
 Number of treatment arms
 SD of HAM-D total score at baseline
3. Results
Overall, data of 4661 individual patients collected in 14 studies
(see Table 1) were used for the present analysis: 2385 patients
(51.2%) received duloxetine, 1573 (33.7%) placebo, and 703 (15.1%)
active comparator. Of all patients included in the present analysis,
the largest proportion (776 patients; 16.6%) came from study HMFS,
followed by study HMCR (684 patients; 14.7%). All other studies
contributed less than 10% of the patients to the present analysis.xetine integrated database included in the Effect Size analysis.
Active comparator (N ¼ 703) Placebo (N ¼ 1573) Total (N ¼ 4661)
42.9 (12.40) 46.8 (16.15) 47.0 (15.87)
457 (65.0) 1020 (64.8) 3026 (64.9)
590 (83.9) 1253 (79.7) 3747 (80.4)
52 (7.4) 141 (9.0) 399 (8.6)
61 (8.7) 179 (11.4) 515 (11.0)
520 (74.0) 1323 (84.1) 3730 (80.0)
159 (22.6) 175 (11.1) 684 (14.7)
24 (3.4) 75 (4.8) 247 (5.3)
486 (69.1) 1116 (70.9) 3348 (71.8)
2 (0; 4) 2 (0; 4) 2 (1; 4)
4.4 (1.8; 12.0) 5.5 (2.0; 12.0) 4.6 (1.8; 12.0)
381 (54.2) 795 (50.5) 2492 (53.5)
4.15 (0.71) 4.26 (0.69) 4.26 (0.69)
18.7 (4.98) 20.1 (4.92) 19.9 (4.99)
19 (15.0; 22.0) 20.0 (17.0; 23.0) 20.0 (17.0; 23.0)
(N ¼ 684) Other (N ¼ 247) Total (N ¼ 4661)
.4) 47 (19.0) 642 (13.8)
7.4) 50 (20.2) 836 (17.9)
1.3) 38 (15.4) 791 (17.0)
1.9) 46 (18.6) 794 (17.0)
.7) 0 (0.0) 589 (12.6)
1.3) 66 (26.7) 1009 (21.6)
4.66) 20.0 (9.62) 22.7 (14.43)
.4) 18 (7.3) 287 (6.2)
5.5) 67 (27.1) 1213 (26.0)
9.8) 84 (34.0) 1329 (28.5)
.2) 43 (17.4) 946 (20.3)
.0) 0 (0.0) 312 (6.7)
2.1) 0 (0.0) 263 (5.6)
.0) 35 (14.2) 311 (6.7)
.77) 1.463 (0.94) 1.466 (0.89)
everity; HAM-D: Hamilton depression scale; IQR: interquartile range (i.e. 25e75%);
pective result; SD: standard deviation; US: United States of America.
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studies had an acute treatment duration of 7e9 weeks. The ma-
jority of patients were recruited in the United States of America
(US).
Table 2 presents an overview of patient demographics by
treatment group and disease characteristics, and the size of study
sites for the complete dataset (i.e. across studies).
About 2/3rd of the patients were female. Patients had a median
age of 45.9 years (interquartile range 34.8e57.3 years), 80.4% (3747)
of the patients were White. Over 28% of the patients had a pre-
existing condition of interest (i.e. linked to depression or in the
same spectrum), with migraine (6.1%), anxiety (4.6%), fatigue
(2.7%), irritable bowel syndrome (2.4%), and myalgia (2.0%) being
the most common. All other pre-existing conditions of interest
were reported by <2.0% of the patients.
More than 50% of the patients had received at least 1 previous
medication indicated for MDD, with ﬂuoxetine (17.4%), sertraline
(16.1%), paroxetine (14.8%), venlafaxine (8.2%), citalopram (6.9%),
and escitalopram (6.2%) being the most common. All other medi-
cations were taken by <5% of the patients.
Mean disease severity at baseline, measured by the HAM-D 17
total score, was 19.9 (SD: 4.99), with an interquartile range of 17e23.
The overall ES between duloxetine and placebo, based on the
HAM-D total score at endpoint (LOCF), was 0.272 (i.e. in favor of
duloxetine) for all patients, and 0.357 excluding patients from
study sites with <10 patients.Table 3a
Analysis of the interaction of study design parameters with the relative effect size of dulo
analyzed separately.
(N ¼ number of patients) Comparison of duloxetine vs.
LSMEAN difference
HAM-D total score at endpoint (LOCF)
Dulox vs. Placebo 1.721
Absolute size of site, i.e. number of patients per site
<10 (N ¼ 599) 1.547
10e14 (N ¼ 740) 2.103
15e19 (N ¼ 665) 1.696
20e24 (N ¼ 628) 2.035
25e29 (N ¼ 507) 1.252
30 (N ¼ 819) 1.908
Relative size of site, i.e. number of patients per site, compared to the median site
Dulox vs. Placebo
<0.5 (N ¼ 246) 1.794
0.5e<1 (N ¼ 1014) 1.312
1e<1.5 (N ¼ 1092) 2.208
1.5e<2 (N ¼ 825) 2.257
2e<2.5 (N ¼ 305) 2.242
2.5e<3 (N ¼ 211) 0.716
3 (N ¼ 265) 1.213
Time to patient recruitment at each site [days]
Dulox vs. Placebo
50 days (N ¼ 2490) 1.901
>50e100 days (N ¼ 617) 2.465
>100e150 days (N ¼ 282) 1.807
>150 days (N ¼ 569) 0.691
Baseline HAM-D score
18; mild (N ¼ 1379) 1.012
19e21 mild to moderate (N ¼ 1031) 2.213
22e24 moderate (N ¼ 860) 1.884
25 severe (N ¼ 688) 2.249
Baseline SDS total score
median (N ¼ 695) 2.032
>median (N ¼ 750) 1.416
The unadjustedmean HAM-D score at endpoint for duloxetine (N¼ 2385) was 10.639 (95
for placebo (N ¼ 1573) 12.799 (95% CI: 12.49, 13.11).
CI: conﬁdence interval; HAM-D: Hamilton depression scale; LOCF: last observation carri3.1. Analysis of factors inﬂuencing ES differences
An overview of the inﬂuence of study design parameters on the
ES, based on the HAM-D total score, is presented in Table 3a.
Absolute study site size showed inconsistent results regarding
an impact on duloxetine vs. placebo HAM-D total score ES differ-
ences. For a graphical representation based on a meta-regression
see Online Fig. 1a.
Relative study site size did not show a signiﬁcant interactionwith
the relative ES between placebo and duloxetine. However, a pattern
can be seen indicating that patients from siteswith on average or just
above the average relative site size within the study showed the
highest ES. For a graphical representation see Online Fig. 1b.
Further, time to recruitment (from study start) did not show a
signiﬁcant interaction with the relative ES between placebo and
duloxetine, as measured by the HAM-D total score. But the last (Q4)
time to recruitment groups, showed a considerably smaller ES. For a
graphical representation see Online Fig. 1c.
As shown in Table 3a, the category of patients having an HAM-D
score closer to the inclusion cutoff of the studies showed the small-
est ES of0.157, whereas for all other baseline HAM-D categories the
ES ranged from 0.279 to 0.333. The differences found between
categories can be considered relevant in terms of signal detection.
An overview of the inﬂuence of study design parameters on a
by-study level on treatment differences in the change from baseline
reporting LSMEAN estimates and 95% CI is presented in Table 3b.xetine vs. placebo. A: Results frommeta-analysis adjusted by Study e Each covariate
placebo
Effect size 95% CI p-Value
0.357 (2.13, 1.31) <0.0001
0.226 (2.70, 0.39) 0.0085
0.332 (3.10, 1.11) <0.0001
0.256 (2.76, 0.63) 0.0018
0.305 (3.13, 0.94) 0.0003
0.180 (2.53, 0.02) 0.0539
0.295 (2.87, 0.95) 0.0001
size of all sites within the study
0.242 (3.61, 0.02) 0.0528
0.213 (2.16, 0.47) 0.0023
0.331 (3.03, 1.38) <0.0001
0.345 (3.25, 1.27) <0.0001
0.316 (3.95, 0.54) 0.0100
0.133 (2.47, 1.03) 0.4225
0.173 (2.96, 0.53) 0.1730
0.275 (2.48, 1.32) <0.0001
0.381 (3.54, 1.39) <0.0001
0.300 (3.35, 0.26) 0.0220
0.122 (1.79, 0.40) 0.2162
0.157 (1.75; 0.27) 0.0072
0.333 (3.07; 1.35) <0.0001
0.279 (2.84; 0.93) 0.0001
0.330 (3.39; 1.11) 0.0001
0.309 (3.09; 0.97) 0.0002
0.218 (2.43; 0.41) 0.0060
% CI: 10.39, 10.89), for active comparator (N¼ 703) 10.445 (95% CI: 10.04; 10.85), and
ed forward; LSMEAN: least square mean; SDS: Sheehan Disability Scale.
Table 3b
Analysis of the interaction of study design parameters with the relative effect size of
duloxetine vs. placebo. B: Results from meta-regression across Studies e Each co-
variate analyzed separately.
(N ¼ number of studies) LSMEAN
estimate
Standard
error
95% CI p-Value
Proportion of patients treated with placebo within study
Dulox vs. Placebo
>20%e40% (N ¼ 9) 1.669 0.366 (2.495, 0.902) 0.0006
>40% (N ¼ 5) 2.124 0.551 (3.324, 0.924) 0.0023
Proportion of completers within study
Dulox vs. Placebo
0%e80% (N ¼ 11) 1.743 0.345 (2.494, 0.991) 0.0003
80% (N ¼ 3) 2.148 0.664 (3.595, 0.702) 0.0071
Mean HAM-D placebo response within study
Dulox vs. Placebo
5 points (N ¼ 6) 2.526 0.411 (3.421; 1.630) <0.0001
>5 points (N ¼ 8) 1.354 0.339 (2.093; 0.616) 0.0018
SD in HAM-D in placebo group within study
Dulox vs. Placebo
7 points (N ¼ 9) 2.309 0.317 (3.000; 1.617) <0.0001
>7 points (N ¼ 5) 1.015 0.413 (1.915; 0.114) 0.0304
Number of post-baseline visits within study
Dulox vs. Placebo
4 or 5 visits (N ¼ 8) 1.719 0.420 (2.644; 0.793) 0.0018
6 visits (N ¼ 3) 2.283 0.656 (3.726; 0.840) 0.0051
>6 visits (N ¼ 3) 1.624 0.686 (3.134; 0.114) 0.0374
Active controlled study
Dulox vs. Placebo
No (N ¼ 7) 1.930 0.431 (2.870; 0.991) 0.0008
Yes (N ¼ 7) 1.723 0.441 (2.683; 0.762) 0.0021
CI: conﬁdence interval; HAM-D: Hamilton depression scale; LSMEAN: least square
mean; SD: standard deviation.
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statistically signiﬁcant interaction as measured by the difference of
the change in HAM-D total score. However, studies with >40%
patients randomized to placebo had an LS mean difference of 2.12
vs. 1.67 points in the HAM-D score when compared to studies with
a lower proportion of patients allocated to placebo. For a graphical
representation see Online Fig. 1d.
Further study characteristics that resulted in low signal detec-
tion in our database were: <80% study completers, a HAM-D pla-
cebo response >5 points, a high variability of placebo response
(SD> 7 points HAM-D),>6 post baseline visits per study, and use of
an active control drug vs. a placebo controlled study (see Table 3b).4. Discussion
We could not ﬁnd single study design parameters or parameters
of study conduct that clearly and statistically signiﬁcantly inter-
acted with the relative ES between placebo and duloxetine as an
active treatment for depression. However, we were able to identify
a group of study characteristics that showed a trend towards higher
vs. lower ES in the trials included in our database.
Signiﬁcant p-values for interaction tests are only an indication
for a variable able to change the effect. However, non-signiﬁcant p-
values do not imply that the studied variable has no impact on the
treatment effect. Given the sample sizes, especially for the meta-
regression analyses where the number of studies is a relevant
factor (i.e. not only number of patients), the descriptive nature of
the interaction should not be neglected. For example, an increase of
the ES by 0.1 would substantially reduce the sample size in future
studies. The absolute reduction in patient numbers needed to
achieve a given power depends on the area inwhich the ES is. An ES
increase from 0.3 to 0.4 has a stronger effect on the sample sizethan an increase from 0.6 to 0.7. If variables like study design can
help to reduce the study size, even small increases in the ES are
relevant as it leads to less patients being exposed to placebo, more
effective use of research budget; and faster implementation of the
study among other consequences of smaller sample size. Thus, for
an exploratory analysis of design aspects and conduct of clinical
studies, this level of evidence is sufﬁcient to discuss possible im-
plications for future studies in MDD.
Factors that may be associated with ES can be classiﬁed into one
of 3 groups, i.e. related to ‘study design’, ‘patient population’, or
‘study implementation’. Aspects of study design which may affect
ES include the proportion of patients receiving placebo relative to
active treatment, and the number of post-baseline visits. Aspects
related to patient populations which may affect ES include the
severity of patients’ depression and the geographical location of the
study sites as well as size of study site (i.e. the number of patients)
and time to patient recruitment are implementation factors.
All study design factors associated directly or indirectly with a
strong placebo response resulted in decreased signal detection.
This was found for absolute and relative size of placebo response,
high variability of the placebo response, and for study designs with
low proportions of patients randomized to placebo (e.g. active
placebo-controlled studies with a 1:2 ratio [placebo:active treat-
ment] had smaller ES than studies with a 1:1 ratio). In a standard
design using an active and placebo-controlled study, the percent-
age of patients randomized to placebo is usually 33%, leading to an
increased placebo effect due to patient and physician expectations,
i.e. because of the greater likelihood of receiving active treatment
(duloxetine or active comparator) than placebo. This could be
overcome by randomizing 50% of the patients to placebo and 25% to
each active treatment in order to achieve the same proportion of
patients receiving placebo as in a standard 2-arm placebo-
controlled study. In addition, the possibility of receiving placebo
should be emphasized, using percentages, in the patient informa-
tion sheet. It is worth to mention that Papakostas and Fava (2009)
found that the percentage of patients randomized to placebo was
the factor having the strongest inﬂuence on signal detection in
MDD trials. This was also conﬁrmed byMallinckrodt et al. (2010) for
Schizophrenia trials, where the signal detection tended to improve
and the mean placebo improvement decreased as the proportion of
patients randomized to placebo increased. Furthermore, consis-
tently with what we suggest, in the case of an active and placebo
controlled trial the results of Mallinckrodt et al. also indicated that
the probability of getting at least one signiﬁcant drug-placebo
contrast within a multi-arm study was maximized by random-
izing more patients to placebo than to the individual active treat-
ment arms. In this case the more convenient allocation ratio seems
to be an equal allocation between the placebo arm and the two
active drugs arms combined (e.g. 2:1:1).
Another factor that might be linked with increased placebo
response, and thus reduced signal detection, was a high number of
post-baseline visits in the study. A similar ﬁnding was also reported
by Dunlop et al. (2012), in a meta-analysis of clinical studies with
venlafaxine and desvenlafaxine. The number of post-baseline visits
depends on the length of the study. For instance, a 12-month study
would, by deﬁnition, include more visits than a 6-week study.
Nevertheless, we recommend that in future studies, visits should be
short as possible, with intervals between visits that are as long as
possible, whilst being compatible with safety and reasonably
achieving the aims of the study.
We also found that relative site size seems to be more important
than absolute site size, as an optimum curve showed that very large
sites, i.e. recruiting high numbers of patients, as well as very small
sites, were associated with a smaller ES relative to sites recruiting
moderate numbers of patients. At larger study sites, reasons for the
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may encourage participation of large numbers of patients, and high
numbers of raters. Conversely, very small sites may not recruit
enough patients to allow regular and stable ratings. Thus, the
critical issue may be the level of recruitment relative to the po-
tential patient base, and the number of patients per rater, i.e. a high
enough number of patients to ensure standardization of the
approach and low enough that the rater is not pressurized by time
constraints.
A further important aspect of study implementationwas time to
patient recruitment, which showed that signal detection was
reduced when patients were recruited late during the course of a
study. This applied both to back-up study sites that were only added
later during the course of the study, and to patients recruited late at
the initial study sites. Both of these scenarios might be a result of
the pressure to recruit patients fast, thus including patients and
centers that are not well suited to the study. Of course, centers that
are included late would also have less time to recruit, and therefore
may have an even stronger recruitment pressure. Also, the use of
back-up centers might reduce signal detection due to differences,
e.g. in the size of patient populations, between them and the
initially selected centers. Thus, adding further centers to speed up
recruitment may harm the scientiﬁc value of a study in MDD. In
addition, it may be pertinent to provide notice of study closure well
in advance to all sites, and from then on only allow patients to be
recruited in numbers which reﬂect the recruitment rate prior to the
closure announcement.
We assessed some variables like “mean HAM-D placebo
response” and “SD in HAM-D in placebo group” that are usually
associated with a low ES via the size of the placebo response.
However the ES between drug and placebo could still be the same,
if the response in the placebo and drug group would increase in
similar proportions. For this to happen, the treatment effect would
really need to be additive to the placebo effect. We notice a
considerable association between large placebo responses and high
SDs in the HAM-D in the placebo group, i.e. the ES is not only
decreased by increasing the denominator but also by decreasing
the numerator.
In terms of patient populations participating in the studies, we
found a decrease in signal detectionwith patients who had baseline
HAM-D scores that were closest to the cutoffs chosen for enroll-
ment into the source trials. We divided the pooled population into
categories based on quartiles according to baseline HAM-D of the
complete integrated dataset. Mild baseline HAM-D values close (3
points) to the cutoff values for study inclusion (18) were found for
34.8% of all patients. These patients showed a much smaller ES of
0.157 relative to the other HAM-D baseline categories, in particular
when compared tomild tomoderate patients with a HAM-D of 19e
21, which showed an ES of 0.333 i.e. the numerically largest ES of
any baseline severity category. Therefore, we hypothesize that the
smaller ES in patients with a baseline HAM-D 18 was probably
due to the proximity to the HAM-D inclusion cutoff of the study
rather than due to a speciﬁc HAM-D severity score that eliminates
mild patients. The problem of baseline score inﬂation in antide-
pressant clinical trials has been identiﬁed in several reports (Kobak
et al., 2007; Rutherford and Roose 2013; Mundt et al., 2007a).
However, traditionally negative study results of patients close to
the lower cutoff were interpreted as a decrease in signal detection
with patients having mild depressive symptoms relative to patients
having moderate or severe symptoms at baseline (Khan et al., 2002,
2004, 2005; Fournier et al., 2010; Kirsh et al., 2008; Rutherford and
Roose, 2013). Instead our results might indicate that baseline score
inﬂation affecting HAM-D baseline values that are only a few points
higher than the study inclusion criteria may have inﬂuenced the
results of those meta-analyses.There has always been a discrepancy between clinical practice
and the accepted evidence from randomized controlled trials as to
whether or not antidepressant drugs are effective in patients with
milder symptoms. Clinicians use antidepressants regularly in these
patients, whereas researchers appear to show that the drugs only
differentiate from placebo in moderate to severe patients. Our hy-
pothesis is that regardless of the level of severity of patients
admitted to a study, possibly due to baseline rating inﬂation, the
lowest category of the study will be the least robust at differenti-
ating active drug from placebo. Thus it may be that the reason for
lack of evidence of efﬁcacy in milder patients is related to their
position in the lowest category of patients recruited to a study and
not to the absolute severity of depression (Posternak et al., 2002;
Simon, 2002; Zimmerman et al., 2002, 2005; Fountoulakis and
Möller, 2012). As the effect of baseline inﬂation may be a meth-
odological artifact of randomized clinical trials, the relevance of the
small ES in mild patients in clinical trials with regard to the success
of treatment of mild depressive patients in clinical practice is
questionable. In particular in clinical trials, the high number of
patients included with HAM-D baseline levels close to minimum
severity, assuming that this is partially due to score inﬂation at
study start, could drag down the overall ES of a study. This would
impair signal detection in clinical trials and could account for the
discrepancy regarding the perceived effectiveness of antidepres-
sants in mild depressive patients in clinical reality vs. what is
usually reported from clinical trials.
One way suggested to improve signal detection in clinical trials
in antidepressants would be to use central investigators as raters
for baseline HAM-D assessments that are blinded to the study entry
criteria. There is, in fact, increasing evidence in the literature that
the use of centralized raters could signiﬁcantly impact the study
sample requirement in MDD trials and lead to signiﬁcantly less
change in mood ratings among patients in the placebo arm (Kobak
et al., 2010). The centralized rating could improve the reliability of
clinical measurement and could theoretically lead to a better and
more consistent interview quality, which should have a positive
impact on signal detection (Kobak et al., 2005). We cannot deny on
the other hand that the use of centralized raters would make the
study execution more complex, therefore decreasing the success
implementation of the study for other reasons. Another way sug-
gested is to use one depression scale (e.g. HAM-D) for study entry
decisions and a different scale (e.g. Montgomery Asperg Depression
Rating Scale, MADRS) for the primary efﬁcacy analysis. However,
some of the studies in our analysis adopted this approach.
In our opinion, the most promising solution for the problem of
baseline inﬂation could be to restrict the primary analysis of a
clinical trial to a population with a higher cutoff (which is blinded
to investigators) compared to the cutoff for study participation.
The country of study conduct was found to be another patient
population-related factor potentially inﬂuencing signal detection.
In particular, we found that centers located in the US showed
higher proportions of those parameters that were found to have a
numerically negative effect on ES compared to placebo (e.g. sites of
very small and very large size, low baseline HAM-D score). How-
ever, the interpretation of these differences was confounded by the
fact that most studies were either performed in one or the other
location, and any differences might have been because of study
design differences instead of country-related differences. However,
some differences in patient recruitment were found, e.g. a larger
proportion of patients were recruited in very small and very large
centers, and had mild symptoms when recruited in studies con-
ducted in the US (based on individual study results). It could be
speculated that ﬁnancial incentives offered in the US (e.g. guaran-
teed health insurance), and advertising for patients, may result in
less severely affected patients seeking enrollment in studies. Our
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literature. In fact, in an extensive analysis, Khin et al. (2011) found a
comparable drug-placebo difference in US and non-US MDD trials.
Therefore, further research into this topic, including studies that
were performed across Europe and the US, are needed.
The current analysis does have potential limitations. It was
performed on an extensive database but all studies were done by
the same sponsor and thus there is possibly some learning effect
over time, which might have confounded or obscured some po-
tential ﬁndings. Pooling of patient level data from various sponsors
might overcome this problem. In addition, the active treatment in
our analyses was mainly duloxetine, thus it not possible to assume
that these results would generalize broadly across antidepressants,
without data from such.
Furthermore, most studies in the database had a treatment
duration of only 8 weeks, and therefore the results might be valid
only for acute treatment studies of MDD and not in longer term
(usually active controlled) or relapse prevention studies. However,
analyses of the relapse prevention studies showed a better per-
formance in signal detection for duloxetine compared to the pre-
sent analysis (Hudson et al., 2007; Perahia et al., 2009).
5. Conclusions
Our results indicate that the use of simpler trials, with a low
number of post-baseline visits, more homogeneous and mid-sized
study sites, and potentially restricting the primary analysis of a
clinical trial to a population with a higher cutoff (which is blinded
to investigators) compared to the cutoff for study participation
would lead to better signal detection of antidepressive efﬁcacy.
Importantly, although active controlled studies are vital for
comparative efﬁcacy evaluations, adding an active control group to
a placebo-controlled clinical trial of MDD may decrease the ability
to separate the effect of active treatments from placebo. In addition,
we suggest that although recruitment pressure may help to keep to
timelines, it may negatively affect the scientiﬁc outcome of the
study by simultaneously reducing the ES.
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